These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 145884)

  • 1. Effects of enzymatic degradation on the subunit composition and biologic properties of human factor VIII.
    Atichartakarn V; Marder VJ; Kirby EP; Budzynski AZ
    Blood; 1978 Feb; 51(2):281-97. PubMed ID: 145884
    [No Abstract]   [Full Text] [Related]  

  • 2. Degradation of bovine factor 8 by plasmin and trypsin.
    Kirby EP; Martin N; Marder VJ
    Blood; 1974 May; 43(5):629-40. PubMed ID: 4274479
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization of the chemotactic activity of casein for neutrophil leucocytes and macrophages.
    Wilkinson PC
    Experientia; 1972 Sep; 28(9):1051-2. PubMed ID: 4269192
    [No Abstract]   [Full Text] [Related]  

  • 4. Degradation of non cross-linked and cross-linked fibrin clots by plasmin, trypsin, chymotrypsin and Brinase.
    Gormsen J; Feddersen C
    Thromb Res; 1974 Aug; 5(2):125-39. PubMed ID: 4278050
    [No Abstract]   [Full Text] [Related]  

  • 5. Isolation, subunit structure, and proteolytic modification of bovine factor VIII.
    Legaz ME; Weinstein MJ; Heldebrant CM; Davie EW
    Ann N Y Acad Sci; 1975 Jan; 240():43-61. PubMed ID: 122888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure of the fibrinogen degradation products.
    Marder VJ; Budzynski AZ
    Prog Hemost Thromb; 1974; 2(0):141-74. PubMed ID: 4137300
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival of rabbit platelets treated in vitro with chymotrypsin, plasmin, trypsin, or neuraminidase.
    Greenberg JP; Packham MA; Guccione MA; Rand ML; Reimers HJ; Mustard JF
    Blood; 1979 May; 53(5):916-27. PubMed ID: 155482
    [No Abstract]   [Full Text] [Related]  

  • 8. Degradation of human fibrinogen by Brinastrase, trypsin and chymotrypsin. An immunological study.
    Gormsen J; Feddersen C; Andersen RB
    Scand J Haematol; 1973; 10(5):349-57. PubMed ID: 4272383
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular structural studies of human factor VIII.
    McKee PA; Andersen JC; Switzer ME
    Ann N Y Acad Sci; 1975 Jan; 240():8-33. PubMed ID: 122889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of trypsin, plasmin, chymotrypsin and thrombin on human heart adenylate cyclase activity.
    Cros GH; Chaptal PA; Serrano JJ
    Res Commun Chem Pathol Pharmacol; 1987 Aug; 57(2):277-80. PubMed ID: 2958913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Porcine factor VIII:C prepared by affinity interaction with von Willebrand factor and heterologous antibodies: sodium dodecyl sulfate polyacrylamide gel analysis.
    Knutson GJ; Fass DN
    Blood; 1982 Mar; 59(3):615-24. PubMed ID: 6800420
    [No Abstract]   [Full Text] [Related]  

  • 12. Degradation of factor VIII coagulant antigen by proteolytic enzymes.
    Rick ME; Popovsky MA; Krizek DM
    Br J Haematol; 1985 Nov; 61(3):477-86. PubMed ID: 2933056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Observation of plasmin on platelet by means of thrombelastograph].
    Nishi A
    Zasshi Tokyo Ika Daigaku; 1971; 29(1):1-9. PubMed ID: 4261342
    [No Abstract]   [Full Text] [Related]  

  • 14. Enzymatic degradation of the factor-VIII-von-Willebrand protein: a unique tryptic fragment with ristocetin cofactor activity.
    Martin SE; Marder VJ; Francis CW; Loftus LS; Barlow GH
    Blood; 1980 May; 55(5):848-58. PubMed ID: 6767513
    [No Abstract]   [Full Text] [Related]  

  • 15. Limited proteolysis of C5b-6: functional stability of the degraded complex.
    Podack ER; Müller-Eberhard HJ
    J Immunol; 1980 Jan; 124(1):332-6. PubMed ID: 6444229
    [No Abstract]   [Full Text] [Related]  

  • 16. Human factor VIII: purification from commercial factor VIII concentrate, characterization, identification and radiolabeling.
    Hamer RJ; Koedam JA; Beeser-Visser NH; Sixma JJ
    Biochim Biophys Acta; 1986 Oct; 873(3):356-66. PubMed ID: 3092864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Blood coagulating properties of immobilized proteases].
    Zubairov DM; Zinkevich OD
    Vopr Med Khim; 1976; 22(2):187-91. PubMed ID: 140525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cryoprecipitation and dextran precipitation in obtaining factor VIII concentrates: comparative protein chemical studies].
    Liebe S; Kubel M; Wegner H
    Z Gesamte Inn Med; 1974 Mar; 29(6):232-6. PubMed ID: 4409089
    [No Abstract]   [Full Text] [Related]  

  • 19. [Methods of preparing Factor VIII. I. Preparation and characteristics of a medium-pure concentrate].
    Perote P; Altamirano P; Aperador R; Camacho Y; Acosta J
    Sangre (Barc); 1984; 29(3):321-8. PubMed ID: 6435268
    [No Abstract]   [Full Text] [Related]  

  • 20. Parallel destruction of factor VIII procoagulant activity and an 85,000 dalton protein in highly purified factor VIII/VWF.
    Cockburn CG; de Beaufre-Apps RJ; Wilson J; Hardisty RM
    Thromb Res; 1981 Feb; 21(3):295-309. PubMed ID: 6454278
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.